ClinicalTrials.Veeva

Menu

Impact of the Coronavirus Disease 2019 (COVID-19) on Sperm Parameters

F

Fertilys

Status

Terminated

Conditions

Infertility, Male
Covid19

Treatments

Diagnostic Test: Sperm analysis

Study type

Observational

Funder types

Industry
Other

Identifiers

NCT04937608
COVID-19 and sperm parameters

Details and patient eligibility

About

This study aims to better understand the effects of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, virus that causes the coronavirus disease 2019 (COVID-19), on male fertility.

Full description

After being informed about the study and potential risks, all patients giving written informed consent will produce a sperm sample by masturbation. Patients will also complete a questionnaire relating to their state of health. Six month following the first sperm sample, patients will produce another sperm sample by masturbation. These sperm parameters will be compared with the ones from a sperm analysis performed less than 2 years before the SARS-CoV-2 infection.

Enrollment

2 patients

Sex

Male

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • All men aged 18 to 45 having a sperm analysis done at the Fertilys fertility center in the last 2 years who have not contracted COVID-19, agreeing to participate in the study and having signed the consent form to participate in the study.
  • All men aged 18 to 45 having a sperm analysis done at the Fertilys fertility center in the last 2 years) who have contracted COVID-19 within the last 6 months, agreeing to participating in the study and having signed the consent form to participate in the study.
  • All men aged 18 to 45 years with a sperm concentration ≥ 15 million/mL, progressive motility ≥ 20% and a percentage of normal forms ≥ 2%.

Exclusion criteria

  • Men aged under 18 and over 45.
  • Men who cannot produce a sperm sample by antegrade ejaculation.
  • Men whose sperm concentration is <15 million/mL, progressive motility <20% and a percentage of normal forms <2%, determined following the production of a "reference" sperm sample, carried out before March 2020, i.e. before the COVID-19 pandemic.

Trial design

2 participants in 2 patient groups

COVID-19 group
Description:
men aged 18 to 45 who have been infected with SARS-CoV-2 in the past 6 months
Treatment:
Diagnostic Test: Sperm analysis
Control group
Description:
healthy men aged 18 to 45 with normal sperm parameters (WHO 2010 criteria) and who have never contracted COVID-19
Treatment:
Diagnostic Test: Sperm analysis

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems